london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Evaluation of topical alpha-2 agonist in the treatment of mixed diabetic maculopathy

Session Details

Session Title: Quick Fire Free Paper 1

Session Date/Time: Thursday 11/09/2014 | 08:00-10:00

Paper Time: 08:25

Venue: Boulevard D

First Author: : H.Al-Nashar EGYPT

Co Author(s): :                  

Abstract Details


To evaluate the efficacy of topical alpha-2 agonist (brimonidine) in the treatment of diabetic maculopathy with mixed edema and ischemia


Patients are in the Zagazig University Hospitals, Zagazig, Sharkya, Egypt.


Twenty two eyes of twenty two patients are involved in this study. All eyes have mixed diabetic maculopathy as diagnosed by fluorescein angiography and spectral domain optical coherence tomography (SD-OCT) (Spectralis HRA-OCT; Heidelberg engineering, Heidelberg, Germany). They were treated by topical brimonidine twice daily for 3 months. Visual acuity, fluorescein angiography & OCT were done for all patients before the beginning of the treatment and every one month for 3 months later on to detect the change in ligMAR visual acuity and the changes in foveal avascular zone (FAZ) size and the macular thickness.


The mean logMAR visual acuity at the beginning of the treatment was 0.9±0.012 and improved to 0.7±0.1 after 3 months (P= 0.03). Size of FAZ was improved after the treatment. The mean central macular thickness was 425±125 µm and changed to 400±23 µm after 3 months (P=0.9).


Alpha 2 agonist (brimonidine) has a role in the treatment of mixed diabetic maculopathy

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy